Processa Pharmaceuticals boosts incentive plan share pool
Processa Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders on July 30, 2026.
Rhea-AI Filing Summary
Processa Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders on July 30, 2026. Shareholders approved an amendment to the company’s 2019 Omnibus Incentive Plan, increasing the number of shares available for issuance under the plan by 200,000 shares.
The amendment received 579,877 votes For, 152,958 Against and 2,700 Abstentions, with 825,288 broker non-votes. Votes were also cast for director nominees, including 710,505 For votes for Justin Yorke with 25,030 Abstentions and 825,288 broker non-votes, and on additional proposals with disclosed vote totals. A quorum was present, representing at least one-third of the voting power as of the June 1, 2026 record date.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Additional shares under incentive plan: 200,000 shares
Votes For incentive plan amendment: 579,877 shares
Votes Against incentive plan amendment: 152,958 shares
+3 more
6 metrics
Additional shares under incentive plan
200,000 shares
Increase in shares available under 2019 Omnibus Incentive Plan approved at 2026 Annual Meeting
Votes For incentive plan amendment
579,877 shares
Shares voting For amendment to 2019 Omnibus Incentive Plan
Votes Against incentive plan amendment
152,958 shares
Shares voting Against amendment to 2019 Omnibus Incentive Plan
Abstentions on incentive plan amendment
2,700 shares
Shares Abstaining on amendment to 2019 Omnibus Incentive Plan
Broker non-votes on incentive plan amendment
825,288 shares
Broker non-votes recorded on the incentive plan amendment proposal
Votes For additional proposal
1,541,664 shares
Shares voting For one of the additional proposals at the 2026 Annual Meeting
Key Terms
2019 Omnibus Incentive Plan, Broker Non-Votes, record date, emerging growth company
4 terms
2019 Omnibus Incentive Plan financial
"amendment to Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan"
Broker Non-Votes regulatory
"Shares | For | Against | Abstain | Broker Non-Vote"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
record date regulatory
"entitled to vote as of the close of business on June 1, 2026, the record date"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When was Processa Pharmaceuticals’ (PCSA) 2026 Annual Meeting and what was the record date?
The 2026 Annual Meeting of Processa Pharmaceuticals (PCSA) was held on July 30, 2026. Shareholders of record at the close of business on June 1, 2026 were entitled to vote, and a quorum of at least one-third of voting power was represented.
Which director nominees of Processa Pharmaceuticals (PCSA) had disclosed vote totals?
Vote tallies are reported for director nominees Justin Yorke, George Ng, Khoso Baluch, James Neal, Geraldine Pannu, and Dr. David Young. For example, Justin Yorke received 710,505 votes For, with 25,030 Abstentions and 825,288 broker non-votes recorded for his nomination.
What other proposals received votes at Processa Pharmaceuticals’ (PCSA) 2026 Annual Meeting?
Beyond director elections and the incentive plan amendment, shareholders voted on additional proposals with reported share counts. One proposal received 1,541,664 For, 12,770 Against and 6,389 Abstentions, while another had 640,726 For, 89,886 Against, 4,923 Abstentions and 825,288 broker non-votes.
Where is Processa Pharmaceuticals (PCSA) located and where is its stock listed?
Processa Pharmaceuticals (PCSA) lists its common stock on the Nasdaq Capital Market under the symbol PCSA. The company’s principal executive offices are at 601 21st Street, Suite 300, Vero Beach, Florida 32960, with a listed telephone number of (772) 453-2899.
AI-generated analysis. How Rhea-AI works. Not financial advice.
